Celgene, Novartis Resolve ADHD Patent Suits

Law360, New York (March 08, 2010, 2:24 PM ET) -- Celgene Corp. and Novartis AG have reached an agreement to settle separate patent infringement suits against KV Pharmaceutical Co. and IntelliPharmaCeutics Corp. over drugs that treat attention deficit hyperactivity disorder, the latter of which brought antitrust counterclaims against the pharmaceutical companies.

Judge Freda L. Wolfson of the U.S. District Court for the District of New Jersey signed orders Thursday that stayed both cases for 60 days in order to permit review of the settlements by certain government authorities. She also ordered that the cases be administratively...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  1. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles